GABA-dopamine relationship in Parkinson's disease striatum
Kish, S.; Rajput, A.; Gilbert, J.; Rozdilsky, B.; Chang, L.J.; Shannak, K.; Hornykiewicz, O.
Advances in Neurology 45: 75-77
1987
ISSN/ISBN: 0091-3952 PMID: 3825737 Document Number: 289378
Document emailed within 1 workday
Related Documents
De Jong, P.J.; Lakke, J.P.; Teelken, A.W. 1984: CSF GABA levels in Parkinson's disease Advances in Neurology 40: 427-430Wustmann, C.; Rudolph, E.; Schwipper, U.; Ranacher, B.; Fischer, H.D.; Schmidt, J. 1982: Effect of nootropic drugs on the dopamine release and dopamine uptake in structures of the rat striatum Acta Biologica et Medica Germanica 41(6): 575-579
Wang, H.Y.; Undie, A.S.; Friedman, E. 1995: Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation Molecular Pharmacology 48(6): 988-994
Kida, E.; Renkawek, K. 1986: Effect of serum and cerebrospinal fluid of patients with Parkinson's disease on the ultrastructural properties of rat striatum in vitro Neuropatologia Polska 24(1): 17-27
Parker, E.M.; Cubeddu, L.X. 1986: Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores Journal of Pharmacology and Experimental Therapeutics 237(1): 179-192
Lewandowska, E.; Kurkowska-Jastrzebska, I.; Lechowicz, W.; Członkowska, A.; Członkowski, A. 1999: Ultrastructural changes in substantia nigra and striatum observed on a mouse model of Parkinson's disease induced by MPTP administration Folia Neuropathologica 37(4): 239-242
Gekht, A.B. 2002: Use of dopamine agonists in the treatment of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 102(9): 54-58
Stoessl, A.J.; de la Fuente-Fernández, R.úl. 2003: Dopamine receptors in Parkinson's disease: imaging studies Advances in Neurology 91: 65-71
Molho, E.S.; Factor, S.A.; Weiner, W.J.; Sanchez-Ramos, J.R.; Singer, C.; Shulman, L.; Brown, D.; Sheldon, C. 1995: The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease Journal of Neural Transmission. Supplementum 45: 225-230
Jenner, P. 2005: A novel dopamine agonist for the transdermal treatment of Parkinson's disease Neurology 65(2 Suppl 1): S3-S5
Olanow, C.Warren. 2002: The role of dopamine agonists in the treatment of early Parkinson's disease Neurology 58(4 Suppl 1): S33-S41
Gerfen, C.R. 2000: Dopamine-mediated gene regulation in models of Parkinson's disease Annals of Neurology 47(4 Suppl 1): S42
Sweet, R.D.; Wasterlain, C.; McDowell, F.H. 1974: Piribedil--an oral dopamine agonist for treatment of Parkinson's disease Transactions of the American Neurological Association 99: 258-260
Löschmann, P.A.; Kunow, M.; Wachtel, H. 1992: Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease Journal of Neural Transmission. Supplementum 38: 55-64
Hornykiewicz, O. 2001: Dopamine and Parkinson's disease. a personal view of the past, the present, and the future Advances in Neurology 86: 1-11
2002: Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved MMW Fortschritte der Medizin Suppl. 2: 88
Streifler, M.; Vardi, Y.; Kesten, M.; Oberman, Z.; Herzberg, M. 1972: Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease Israel Journal of Medical Sciences 81(5): 597-601
Ahlskog, J.Eric.; Maraganore, D.M.; Uitti, R.J.; Uhl, G.R. 2002: Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease JAMA 288(3): 311; Author Reply 312-3
Albin, R.L.; Nichols, T.E.; Frey, K.A. 2002: Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease JAMA 288(3): 311
Bode, M. 2009: Dopamine agonist therapy in early Parkinson's disease. a survey of a Cochrane review Ugeskrift for Laeger 171(41): 2996-2999